Pepper Bio

4:15 PM - 4:30 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104A
Like real-time traffic data revolutionized how we drive, Pepper Bio, the world’s first transomics company, is revolutionizing drug discovery.

By integrating phosphoproteomic data – the ‘real time’ traffic data of drug discovery, central to understanding oncology, neurology, and inflammatory diseases – with genomic, transcriptomic, and proteomic data, Pepper’s bioplatform draws out true global, functional, and causal understanding of biological function. With its “Google Maps for drug discovery,” Pepper reveals hazards and roadblocks that researchers may face when developing a new drug to illuminate the fastest, safest path to drug discovery and significantly improve the likelihood of success for clinical trials.

Launched from stealth in 2021 and based in Boston, Massachusetts, Pepper Bio is led by co-founders Chief Executive Officer Jon Hu and Chief Science Officer Samantha Dale Strasser, PhD.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Transomic bioplatform that helps researchers discover therapies for untreated disease
Development Phase of Primary Product:
Other/Not Applicable
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Co-founder and Chief Science Officer
Pepper Bio